We have been certified as a designated project of the National Strategy Special Zone, “Pharmaceutical development project by establishing Oligonucleotide Pharmaceutical API Development Center”, which we are currently in the process of building.

This project will establish a new facility for oligonucleotide drug substance manufacturing and R&D. Additionally, the building will feature a new manufacturing technology, which will be the first of its kind in Japan. The new facility will provide a state-of-the-art pharmaceutical manufacturing area to manufacture therapeutic drugs for oligonucleotides, which is expected to rapidly expand as advanced medicine.

This new facility will allow us to grow further as a world leading contract development and manufacturing organization for oligonucleotides.

Read more: Special zone certification press release _ 20180626